BUSINESS● LOWJun 24 · Jun 24, 2026, 10:52 AM
Lilly inks R&D deal worth up to $1.9B with China’s Abbisko
Seeking Alpha Tech
Lilly has finalized a research and development agreement with China's Abbisko, potentially valued at up to $1.9 billion. This represents a substantial collaboration in the pharmaceutical industry.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESSnowCapital markets, big winners of the Dangote IPOJeune AfriqueBUSINESS9m ago10 small-cap industrial stocks with weakest momentum gradesSeeking Alpha Tech